Compare Edwards Lifesciences Corporation Common Stock (EW) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs KKR & Co Inc — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $83.84 (market cap $48.56B), while KKR & Co Inc trades at $91.6 (market cap $80.39B). The key difference: KKR & Co Inc is the larger of the two by market cap, and KKR & Co Inc pays a 0.87% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | KKR | |
|---|---|---|
Market Cap | $48.56B | $80.39B |
Volume | 6,520,488 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $95.18 | $142.75 |
52-Week Low | $72.65 | $83.88 |
Enterprise Value | $45.01B | $2.95B |
Typical Hold Time | — | 67 Days |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KKR trades at $89.67, down 1.1% on the day, with strong analyst support (89% buy ratings) and a $123.30 consensus price target suggesting 38% upside. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. The company maintains solid profitability with 14.97% net income margin and 10.99% ROE, while recent business developments include strategic joint ventures and asset sales across global markets.
KKR presents a compelling investment case with strong institutional backing and consistent earnings growth, though technical indicators show bearish momentum. Key risks include market volatility and execution challenges in global investments. The significant discount to analyst targets and recent strategic moves position the stock for potential recovery despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
